APUS Apimeds Total Asset Value of Company

Apimeds Pharmaceuticals (APUS) is developing a comprehensive approach to the therapy of sclerosis and inflammatory processes, establishing a foundation for saving critically ill patients. Business development relies on the promotion of purified bee venom injections under strict monitoring of trial costs, with total assets amounting to 69.09. The linear price action on this chart is supplemented by data on the implementation of computer biomodeling and robotics to automate drug development.

APUS (Apimeds Pharmaceuticals US) Company Total Assets history from 05/10/2025 to 10/29/2026

Analytical breakdowns and data insights for company apimedsus.com (APUS)

- current quotes and average value forecast:

Market Chart Apimeds Pharmaceuticals US|APUS - Price Target Chart

- market capitalization data:

Market Valuation Apimeds Pharmaceuticals, Inc.|APUS - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Apimeds Pharmaceuticals|APUS - Book Capitalization|Market Capitalization to Book Value Ratio apimedsus.com|APUS - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Apimeds Pharmaceuticals|APUS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Apimeds Pharmaceuticals US|APUS - Company Aggregate Debts|Debts to Book Capitalization Apimeds Pharmaceuticals, Inc.|APUS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Apimeds Pharmaceuticals

Fundamental valuation:Apimeds Pharmaceuticals

Manufactured products of Apimeds Pharmaceuticals, Inc.

A stable cash flow from the sale of bee venom-based drugs forms the foundation of the capital base of Apimeds Pharmaceuticals (APUS). Total assets, reconstructed via ROA profitability, reflect the company's aggregate resource volume, where a lack of dynamics in the change of the company's financial assets signals business stagnation despite the current stability of operational activities.

Key competitors

JAZZ - Company Total Asset Base|Aggregate Company Assets Cytokinetics, Incorporated|PTC Therapeutics Inc - Total Asset Value of Company|Company Total Assets SRRK|CNTA (Centessa Corp) - Aggregate Asset Value|Company Total Assets DYN (Dyne Therapeutics, Inc.)|Company Total Assets edgewisetx.com EWTX|RAPP - Aggregate Company Assets|Aggregate Asset Value ALMS (Alumis Inc)|Kempharm (ZVRA) - Aggregate Company Assets|Cumulative Company Assets Contineum Corp|LRMR (Larimar Therapeutics) - Company Total Assets|Company Total Assets Capricor|Cumulative Company Assets TRDA (Entrada Therapeutics, Inc.)|PTHS (Channel Therapeutics Inc.) - Aggregate Asset Value|Aggregate Company Assets MediciNova MNOV|SER: Total Business Assets|BioXcel Therapeutics - Company Total Assets|Company Assets ProMIS Neurosciences|AEON (aeonbiopharma.com) - Cumulative Company Assets|NLS Pharmaceutics (NLSP) - Company Total Assets|Aggregate Company Assets Bionomics Ltd.|HUGE: Aggregate Asset Value|Aggregate Company Assets Reata Pharmaceuticals (RETA)